Home > Insider Trading > Filing (0001209191-18-032950)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1618835	Evofem Biosciences Inc.	EVFM	Investment Advice (6282)	D0

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
914208	Ltd. Invesco	1555 Peachtree Street Ne Suite 1800 Atlanta GA 30309		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2018-05-22	2,127,659	$4.69	9,165,157	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants	Acquisiton	2018-05-22	2,127,659	$0.01	425,531	$7.50

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,127,659	2018-05-24	2018-05-24	No	4	P	Indirect

Footnotes

The common stock and warrants were purchased from the underwriters in a public offering pursuant to a registration statement on Form S-1 (333- 224958). The shares of common stock and warrants were purchased at the public offering price.
Invesco Ltd. is the beneficial owner of 9,165,157 shares of common stock and 2,127,659 warrants acquired by its affiliates, Invesco Perpetual High Income Funda and Invesco Perpetual Income Fund.
Invesco Asset Management Ltd. is a subsidiary of Invesco Ltd., and it advises Invesco Perpetual High Income Fund and Invesco Perpetual Income Fund.
As described in the Neothetics, Inc. Registration Statement on Form S-4 (File No. 333-221592) voting and investment power over the common stock and warrants held by Invesco Perpetual High Income Fund and Invesco Perpetual Income Fund is exercised by the directors of Invesco Asset Management Ltd. Neothetics, Inc. changed its name to Evofem Biosciences, Inc. on January 17, 2017.